Answers are grounded in this paper and cite their sources.
BACKGROUND: . OBJECTIVES: We explored the role of p53 in de novo activation of VWF expression in cancer cells of non-endothelial/megakaryocytic origin. METHODS: The analyses of 100 VWF-positive cancer cell lines revealed NF-IB downregulation and/or p53 mutation. Using p53-null and plakoglobin-deficient H1299 lung carcinoma cell line, we examined the effect of exogenously expressed p53 (wild type and mutants) on VWF expression. The findings were validated in ovarian cancer lines with endogenous p53 variants. We assessed the functional consequences and molecular mechanisms of de novo VWF expression. RESULTS: activated de novo expression of VWF by interacting with NF-IB and GATA6, preventing NF-IB's repressive and promoting GATA6's activating functions on the VWF promoter. VWF expression mediates cancer cell-platelet heteroaggregate formation. Plakoglobin coexpression or VWF knockdown reversed these effects. CONCLUSION: in cancer cells and reveal plakoglobin as a potent antagonist of this pathway.
No takes yet. Share an insight, caveat, or question.
Seyyedi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: